President signs executive orders aimed at addressing high drug prices
President Trump Friday signed three executive orders aimed at lowering the price of prescription drugs, with actions targeting federally qualified health center insulin and EpiPen discounts; the importation and re-importation of prescription drugs from foreign countries; and drug manufacturer rebates and discounts traditionally negotiated by and given to pharmacy benefit managers.
See Friday’s AHA Special Bulletin for highlights.
Related News Articles
Headline
The White House yesterday launched TrumpRx, the direct-to-consumer platform that will serve as a hub to direct cash-paying consumers to drug manufacturers…
Headline
The Department of Labor has issued a proposed rule to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to disclose…
Headline
The Department of Health and Human Services Office of Inspector General Jan. 27 released a bulletin addressing how direct-to-consumer drug programs can sell…
Headline
The Centers for Medicare & Medicaid Services Jan. 27 announced 15 drugs under Medicare Parts D and B selected for the third round of price negotiations.…
Headline
The White House released a health care plan Jan. 15 addressing drug prices, health insurance premiums and price transparency efforts. The plan includes…
Headline
The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver…